Mon, Jul 28, 2025
Volume 19, Issue 2 (Mar-Apr 2025)
mljgoums 2025, 19(2): 10-14 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Konikkara K P, Mukundan A, John R. SARS-CoV-2 IgG antibody response to a viral vector vaccine among health care workers in a tertiary care hospital. mljgoums 2025; 19 (2) :10-14
URL: http://mlj.goums.ac.ir/article-1-1663-en.html
URL: http://mlj.goums.ac.ir/article-1-1663-en.html
1- Department of Microbiology Government Medical College Thrissur, Kerala, India , kavithageejo@gmail.com
2- Department of Microbiology Government Medical College Thrissur, Kerala, India
2- Department of Microbiology Government Medical College Thrissur, Kerala, India
Abstract: (205 Views)
Background: The surge of COVID-19 has weighed heavily on health-care systems and hospitals. Health-care workers are at high risk of exposure both in the community and workplace when providing care to patients. Quantitative assays to detect antibodies against SARS COV-2 help to determine individual antibody titer and in longitudinal monitoring of antibody response. The present study was undertaken as there is not much data available regarding the presence of SARS COV-2 antibodies among health care workers in Kerala. The objective was to estimate the IgG antibody response and to find out the associated factors in vaccinated health-care workers.
Methods: A cross-sectional study was conducted among 187 vaccinated health- care workers. The blood sample was collected from health care workers and quantitative determination of humoral antibodies (Including IgG) was done by Chemiluminescence immunoassay. The antibody response was correlated with various factors. Analysis was done using the software IBM SPSS Version 25.
Results: The seroconversion rate following the Covishield vaccine was found to be 99.47% with mean, median, and standard deviation of antibody titer being 1291.0, 311.40 and 1792.500, respectively. Statistical significance in antibody titer was observed among different categories of health care workers and in those with previous COVID-19 infection. Higher titer was noted within 3 months of vaccination and thereafter waning of titer was seen which was also statistically significant.
Conclusion: No correlation was observed with age, gender, co-morbidities, area of work and Body Mass Index (BMI). Vaccination plays a major role in containing the infection. The immune response among vaccinated health-care workers was satisfactory.
Methods: A cross-sectional study was conducted among 187 vaccinated health- care workers. The blood sample was collected from health care workers and quantitative determination of humoral antibodies (Including IgG) was done by Chemiluminescence immunoassay. The antibody response was correlated with various factors. Analysis was done using the software IBM SPSS Version 25.
Results: The seroconversion rate following the Covishield vaccine was found to be 99.47% with mean, median, and standard deviation of antibody titer being 1291.0, 311.40 and 1792.500, respectively. Statistical significance in antibody titer was observed among different categories of health care workers and in those with previous COVID-19 infection. Higher titer was noted within 3 months of vaccination and thereafter waning of titer was seen which was also statistically significant.
Conclusion: No correlation was observed with age, gender, co-morbidities, area of work and Body Mass Index (BMI). Vaccination plays a major role in containing the infection. The immune response among vaccinated health-care workers was satisfactory.
Research Article: Original Paper |
Subject:
Microbiology
Received: 2023/05/8 | Accepted: 2023/11/26 | Published: 2025/07/28 | ePublished: 2025/07/28
Received: 2023/05/8 | Accepted: 2023/11/26 | Published: 2025/07/28 | ePublished: 2025/07/28
References
1. WHO COVID-19 Dashboard weekly update published on 23rd. 2022. [View at Publisher]
2. Jeewandara C, Kamaladasa A, Pushpakumara PD, Jayathilaka D, Aberathna IS, Rasikangani Danasekara DRS, et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat commun 2021;12(1):4617. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Rafi AM, Tomy MM, Thomas R, Valsan C, Unnikrishnan UG, Innah SJ, et al. Serosurveillance of SARS-CoV-2 among the health-care Workers of a Tertiary Care Teaching Institution during the Post Lockdown Phase in Central Kerala, India. J Clin Diagn Res. 2021;15(7):13-7. [View at Publisher] [DOI] [Google Scholar]
4. Singh AK, Phatak SR, Sing R, Bhattacharjee K, Singh NK, Gupta A, et al. Antibody response after second dose of ChAdOx1-nCOV (Covishield TM) and BVB-125 (Covaxin TM) among health care workers in India: Final results of cross- sectional coronavirus vaccine-induced antibody titer (COVAT) study. Vaccine. 2021;39 (44): 6492-6509. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Subbarao S, Warrener LA, Hoschler K, Perry KR, Shute J, Whitaker H, et al. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021;26(12):2100329 [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. Eur J Clin Microbiol Infect Dis. 2020;39(12):2271-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Hoque A, Barshan AD, Chowdhury FUH, Fardous J, Hasan MJ, Saeed Khan Md A, et al. Antibody Response to ChAdOx1-nCoV-19 Vaccine Among Recipients in Bangladesh: A Prospective Observational Study. Infect Drug Resist. 2021;14:5491-500. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Haque MA, Tarik MH, Amin MR, et al. Antibody Response of Covishield Vaccine among Health Care Workers at Rajshahi Medical College Hospital- A Cross-Sectional Study. TAJ .2021;34:(2):01-08 [View at Publisher] [DOI] [Google Scholar]
9. Mahadevaiah A, Doddamadaiah C,KS S, Nanjappa MC. Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre. Indian J Med Microbiol 2022;40(2):200-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Njarekkattuvalappil SK, Bhaskaran R, Raj S, Jose P, Rafi AM, Thomas J, et al. Sero surveillance among health-care workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: Prospective cohort study. Sechenov Medical Journal. [View at Publisher] [DOI] [Google Scholar]
11. Balasubramanian R, Menon T. Antibody Response against Covid-19 among Vaccinated Health Care Workers - A Cross-Sectional Serosurveillance Study. Asian J Med Res. 2022;11(2):31-6. [View at Publisher]
12. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999-1009. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Jabal KA, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from health-care workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):2100096. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Uysal EB, Gümüş S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID‐19 vaccination of health-care workers. J Med Virol. 2022;94(3):1060-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Bhuiyan TR, Akhtar M, Khaton F, Ara Rahman SI, Ferdous J, Alamgir ASM, et al. Covishield vaccine induces robust immune responses in Bangladeshi adults. IJID Reg. 2022;(3):211-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Murhekar MV, Bhatnagar T, Thangaraj JW, Saravanakumar V, Kumar MS, Selvaraju S, et al. SARS-CoV-2 seroprevalence among the general population and health-care workers in India, December 2020-January 2021. Int J Infect Dis. 2021;108:145-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Ali H, Alahmad B, Al-Shammari AA, Alterki A, Hammad M, Cherian P, et al. Previous COVID-19 Infection and Antibody Levels after Vaccination. Front public health 2021;9:778243. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 2021;595(7867):421-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):e84 [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Assaid N, Arich S, Charoute H, Akarid K, Ezzikouri S, Maaroufi A, et al. Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Health-care Workers. Vaccines 2022;10(3):465. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.